- Home
- RIGL vs XPER Comparison
RIGL vs XPER Comparison
Compare RIGL & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- XPER
- Stock Information
- Founded
- RIGL 1996
- XPER 1990
- Country
- RIGL United States
- XPER United States
- Employees
- RIGL N/A
- XPER N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- XPER Semiconductors
- Sector
- RIGL Health Care
- XPER Technology
- Exchange
- RIGL Nasdaq
- XPER Nasdaq
- Market Cap
- RIGL 335.5M
- XPER 370.5M
- IPO Year
- RIGL 2000
- XPER 2003
- Fundamental
- Price
- RIGL $18.41
- XPER $8.03
- Analyst Decision
- RIGL Buy
- XPER Strong Buy
- Analyst Count
- RIGL 5
- XPER 3
- Target Price
- RIGL $36.40
- XPER $19.00
- AVG Volume (30 Days)
- RIGL 170.2K
- XPER 266.5K
- Earning Date
- RIGL 08-05-2025
- XPER 08-04-2025
- Dividend Yield
- RIGL N/A
- XPER N/A
- EPS Growth
- RIGL N/A
- XPER N/A
- EPS
- RIGL 2.08
- XPER N/A
- Revenue
- RIGL $203,077,000.00
- XPER $488,877,000.00
- Revenue This Year
- RIGL $14.41
- XPER $0.50
- Revenue Next Year
- RIGL $15.97
- XPER $8.71
- P/E Ratio
- RIGL $8.92
- XPER N/A
- Revenue Growth
- RIGL 70.16
- XPER N/A
- 52 Week Low
- RIGL $7.48
- XPER $6.29
- 52 Week High
- RIGL $29.82
- XPER $11.08
- Technical
- Relative Strength Index (RSI)
- RIGL 37.91
- XPER 55.55
- Support Level
- RIGL $18.35
- XPER $7.61
- Resistance Level
- RIGL $19.21
- XPER $7.90
- Average True Range (ATR)
- RIGL 0.89
- XPER 0.21
- MACD
- RIGL -0.33
- XPER -0.01
- Stochastic Oscillator
- RIGL 2.15
- XPER 71.54
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About XPER Xperi Inc.
Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.